Regeneron Gets CHMP Backing of Linvoseltamab
A class action lawsuit was filed against Regeneron Pharmaceuticals, Inc. (REGN) by Levi & Korsinsky on January 7, 2025. The ...
Regeneron Pharmaceuticals said on Monday its experimental gene therapy showed improved hearing in 10 of 11 children between ...
Regeneron Narrows Approval Aspirations for Lymphoma Bispecific, Citing ‘Competitor Developments’
The company will push through with an accelerated approval application for odronextamab in follicular lymphoma, leaving ...
Feb. 24 meeting of the full Nassau County Legislature, Deputy Minority Leader Arnold W. Drucker honored District 16's seven ...
Regeneron has won a court ruling that will make it harder for U.S. authorities to win a lawsuit accusing it of paying illegal ...
A gene therapy from Regeneron Pharmaceuticals Inc. improved hearing in nearly all deaf children in a clinical trial, results ...
A year after the FDA rejected its marketing application for CD20xCD3 bispecific antibody odronextamab to treat two common ...
Regeneron’s gene therapy, dubbed DB-OTO, is a cell-selective AAV gene therapy for children with hearing loss stemming from a ...
Ten of 11 children born with a rare form of congenital hearing loss experienced improvements after receiving the company’s ...
Shares of Regeneron Pharmaceuticals Inc. REGN shed 2.28% to $706.94 Wednesday, on what proved to be an all-around mixed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback